Topic: BPH

When All Else Fails: Holmium Laser Enucleation of the Prostate as Retreatment for BPH

Nicole L. Miller, MD, FACS, Associate Professor of Urology at Vanderbilt University Medical Center, discusses Holmium laser enucleation of the prostate (HoLEP), particularly focusing on the retreatment setting. AUA guidelines have recently been updated and now mirror EAU guidelines which suggest sizing a prostate before determining treatment options. Dr. Miller examines case studies that underscore the effectiveness of HoLEP in removing large prostates after the patients had previously undergone unsuccessful treatments, including transurethral resection of the prostate (TURP) and prostatic urethral lift. She then analyzes outcomes of a study that compared primary HoLEP (pHoLEP) to retreatment (rHoLEP) observing that the retreatment setting patients experienced shorter operative times, shorter length of stay, had less tissue resected, and had a higher rate of urethral stricture and clot retention. In spite of its utility, HoLEP has not been widely adopted and represents 4% of procedures, which Dr. Miller attributes to the steep learning curve associated with HoLEP. Lastly, she enumerates the barriers within the US medical system to physicians undertaking the HoLEP learning process and concludes that while Europe has numerous options for physicians to learn the technique, the American focus on robotic surgery means that fewer students learn open orifices surgical procedures.

Read More

Treating BPH: Comparing HoLEP, Rezum, and Urolift

Scott M. Cheney, MD, reviews the background and practical application of minimally-invasive surgical therapies and definitive therapies for benign prostatic hyperplasia (BPH). He then discusses patient selection for these therapy options based on recommendations, level of evidence, and comparative outcomes.

Read More

Men’s Health from the Heart

Tobias S. Kohler, MD, MPH, demonstrates the correlation between cardiac pathology and erectile function, other sexual function, testosterone levels, and lower urinary tract symptoms (LUTS). To illustrate this, he describes the methodology and results of his Cardio-Urologic Pathology/Prevalence Interplay Determination (CUPID) study. He also discusses ED risk factors, sex hormone binding globulin (SHBD), and the connection between testosterone levels and benign prostatic hyperplasia (BPH).

Read More

Join the GRU Community

- Why Join? -